preload reserve in dilated cardiomyo-pathy / C. Heymes, M. Vanderlieyden, J
Bronzwaer // Circulation. - 1999. -V. 99. - P. 3009-3016.
157.
Ikeda A. Bronchodilating effects of combined therapy of ipratropium
bromide and salbutamol for stable COPD: comparison with ipratropium bro
mide alone / Ay' Ikeda // Chest. - 1995. V. 107. - P. 401-405.
158.
James A. Airway smooth muzcle in health and disease; methods of
measurement and relation to function / A. James // Carroll N Eur Respir J. -
2000. V. 15. - P. 782-789.
I 59.
Jones P. Why Quality of Life measures should be used in the treatment
ofpatients with respiratory illnesses / P. Jones // Monaldi Arch. Dis. Chest. -
1997. -Vol. 49. - P. 79-82.
160.
Jones P.W. Quality of life changes in COPD patients treated with sal-
meterol / P.W. Jones., Т.К. Bush // Am J Respir Crit Care Med. - 1997. V
155. - P. 1283-1289.
161.
Jonson M. Alternative mechanisms for longacting (32-adrenergic agon
ists in COPD / M. Jonson, S. Rennard // Chest. - 2001. - V. 120. - P 258-270.
162.
Kalra L. Effect of nifedipine on physiologic shunting andoxygenation
in chronic obstructive pulmonary disease / L. Kalra, M.F. Bone // Airier. J.
Med. -1993.-V.94.-P.419-423
163.
Karpel J.P A comparison of inhaled ipratropium, oral theophylline plus
inhaled betaagonist, and the combination of all three in patients with COPD
J.P. Karpel. - 1994. Vol. 105. - P. 1089-1094
164.
Katz A. Cellular action and pharmacology of the calcium channel
blockingdrugs / A. Katz // J. Amer. Coll. Cardiol. - 1996. -V. 28. - P. 522-529
165.
Katz A.M. Protein families that mediated Ca2+ signaling in the cardi
ovascular system / A.M. Katz/ / Am J Cardiol. 1996. V. 78. - P.:2-
166.
Kawakami Y. Molecular studies of bronchial asthma, sarcoidosis and
angiotensin converting enzyme inhibitor-induced cough / Y. Kawakami, M.
Munakata, E. Yamaguchi // Respirology. - 1998. - V. 3(1). P. 45-9.
